Quick Answer
ONCOLYTICS BIOTECH INC reported Net Income of -$28.76 million for fiscal year 2025.
ONCOLYTICS BIOTECH INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$28.76M -26.2% |
-$22.79M | — | — | — | — |
| Diluted EPS | -$0.30 +0.0% |
-$0.30 | — | — | — | — |
| Total Assets | $7.58M -43.5% |
$13.42M -65.4% |
$38.82M +4.0% |
$37.33M -18.6% |
$45.88M +33.6% |
$34.35M +74.7% |
| Cash and Equivalents | $5.20M -53.0% |
$11.08M | — | — | — | — |
| Stockholders Equity | -$3.80M -215.2% |
$3.30M -83.2% |
$19.60M | — | — | — |
| R&D Expense | $13.31M -13.8% |
$15.44M -12.8% |
$17.71M +14.8% |
$15.43M +19.4% |
$12.92M -0.2% |
$12.95M +19.7% |
| Operating Income | -$28.73M -12.5% |
-$25.54M | — | — | — | — |
| Shares Outstanding | 108.02M +35.0% |
80.02M | — | — | — | — |
- ONCOLYTICS BIOTECH INC reported Net Income of -$28.76 million for fiscal year 2025.
- ONCOLYTICS BIOTECH INC showed a decrease of -26.2% in Net Income compared to the prior fiscal year.
- ONCOLYTICS BIOTECH INC reported Diluted EPS of $0.30 per share (loss) for fiscal year 2025.
- ONCOLYTICS BIOTECH INC showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- ONCOLYTICS BIOTECH INC reported Total Assets of $7.58 million for fiscal year 2025.
- ONCOLYTICS BIOTECH INC showed a decrease of -43.5% in Total Assets compared to the prior fiscal year.
- ONCOLYTICS BIOTECH INC reported Cash and Equivalents of $5.20 million for fiscal year 2025.
- ONCOLYTICS BIOTECH INC showed a decrease of -53.0% in Cash and Equivalents compared to the prior fiscal year.
- ONCOLYTICS BIOTECH INC reported Stockholders Equity of -$3.80 million for fiscal year 2025.
- ONCOLYTICS BIOTECH INC showed a decrease of -215.2% in Stockholders Equity compared to the prior fiscal year.
- ONCOLYTICS BIOTECH INC reported R&D Expense of $13.31 million for fiscal year 2025.
- ONCOLYTICS BIOTECH INC showed a decrease of -13.8% in R&D Expense compared to the prior fiscal year.
- ONCOLYTICS BIOTECH INC reported Operating Income of -$28.73 million for fiscal year 2025.
- ONCOLYTICS BIOTECH INC showed a decrease of -12.5% in Operating Income compared to the prior fiscal year.
- ONCOLYTICS BIOTECH INC reported Shares Outstanding of 108.02 million shares for fiscal year 2025.
- ONCOLYTICS BIOTECH INC showed an increase of +35.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: